Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699596 | 0.79 | CDC7 (0.46) | CDC7ADORA1AAK1ADORA2BADORA3 | |
| SCHEMBL14705835 | 0.76 | ABL1 (0.58) | ADORA1 | |
| SCHEMBL19699524 | 0.75 | ADORA3 (0.50) | ADORA1AAK1ADORA2BADORA3ADORA2A | |
| SCHEMBL19699609 | 0.73 | ADORA1 (0.73) | CDC7ADORA1ADORA3ADORA2ANPC1 | |
| SCHEMBL3433303 | 0.70 | HSP90AA1 (0.49) | CDC7ADORA2ANPC1RAB9ASYK | |
| SCHEMBL19699460 | 0.70 | L3MBTL1 (0.51) | CDC7ADORA1NPC1RAB9A | |
| SCHEMBL19699600 | 0.70 | MKNK1 (0.55) | CDC7ADORA1 | |
| SCHEMBL17491530 | 0.69 | SMN1; SMN2 (0.42) | ADORA1AAK1ADORA2BADORA3ADORA2A | |
| SCHEMBL20832586 | 0.69 | CDC7 (0.46) | CDC7ADORA1AAK1ADORA2BADORA3 | |
| SCHEMBL19531641 | 0.68 | BRAF (0.56) | AAK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CDC7 899/4885ADORA1 2592/4885AAK1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.